Axel Merseburger1, Anne Bro Falkenberg2, Olga J Kornilova3. 1. University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany. axel.merseburger@uksh.de. 2. Ferring Pharmaceuticals, Kay Fiskers Plads 11, Copenhagen, Denmark. 3. Ferring International Center, Chemin de la Vergognausaz 50, Saint-Prex, Switzerland.
Abstract
PURPOSE: To study the current level of patients' awareness, and patient-health care provider (HCP) dialogue with respect to treatment-related risks, especially cardiovascular risk (CVR) associated with advanced prostate cancer (PCa) treatment. METHODS: This 10-min online survey summarised data by treatment, region, and CVR (high or low). RESULTS: Of the 411 patients, 83% were at high CVR while only 8% patients were aware of CVR associated with PCa treatment, majority of which (80%) were informed about this risk by HCPs. No significant difference in treatment approach was reported, regardless of patient's CVR status. Compared to other potential risks, patients were more likely to initiate discussion about heart problems with HCPs (38% patients). When prompted, 26% patients rated heart problems as the most concerning risk factor, and this concern was twice in patients with high CVR (28%) versus low CVR (14%). Lifestyle modifications were made by 64% patients, of which 45% patients reported an improvement in overall well-being. Improved diet was the most adopted lifestyle modification. CONCLUSION: There is a need to enhance a constant patient-HCP dialogue, and both groups need to make a conscious effort in that direction. This would help in increasing patients' awareness of risks, having better treatment choice and acceptance, and reducing side-effects.
PURPOSE: To study the current level of patients' awareness, and patient-health care provider (HCP) dialogue with respect to treatment-related risks, especially cardiovascular risk (CVR) associated with advanced prostate cancer (PCa) treatment. METHODS: This 10-min online survey summarised data by treatment, region, and CVR (high or low). RESULTS: Of the 411 patients, 83% were at high CVR while only 8% patients were aware of CVR associated with PCa treatment, majority of which (80%) were informed about this risk by HCPs. No significant difference in treatment approach was reported, regardless of patient's CVR status. Compared to other potential risks, patients were more likely to initiate discussion about heart problems with HCPs (38% patients). When prompted, 26% patients rated heart problems as the most concerning risk factor, and this concern was twice in patients with high CVR (28%) versus low CVR (14%). Lifestyle modifications were made by 64% patients, of which 45% patients reported an improvement in overall well-being. Improved diet was the most adopted lifestyle modification. CONCLUSION: There is a need to enhance a constant patient-HCP dialogue, and both groups need to make a conscious effort in that direction. This would help in increasing patients' awareness of risks, having better treatment choice and acceptance, and reducing side-effects.
Authors: Giorgio Gandaglia; Maxine Sun; Ioana Popa; Jonas Schiffmann; Vincent Trudeau; Shahrokh F Shariat; Quoc-Dien Trinh; Markus Graefen; Hugues Widmer; Fred Saad; Alberto Briganti; Francesco Montorsi; Pierre I Karakiewicz Journal: Clin Genitourin Cancer Date: 2014-12-09 Impact factor: 2.872
Authors: Mieke Van Hemelrijck; Hans Garmo; Lars Holmberg; Erik Ingelsson; Ola Bratt; Anna Bill-Axelson; Mats Lambe; Pär Stattin; Jan Adolfsson Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Paul L Nguyen; Ming-Hui Chen; Karen E Hoffman; Ronald C Chen; Jim C Hu; Charles L Bennett; Michael W Kattan; Oliver Sartor; Karen Stein; Anthony V D'Amico Journal: BJU Int Date: 2011-11-15 Impact factor: 5.588
Authors: I Latorzeff; G Ploussard; J Guillotreau; F Jonca; P Labarthe; G Rollin; J-B Beauval; A Pathak Journal: Cancer Radiother Date: 2016-06-22 Impact factor: 1.018
Authors: Henry K Tsai; Anthony V D'Amico; Natalia Sadetsky; Ming-Hui Chen; Peter R Carroll Journal: J Natl Cancer Inst Date: 2007-10-09 Impact factor: 13.506
Authors: Reina Haque; Marianne UlcickasYood; Xiaoqing Xu; Andrea E Cassidy-Bushrow; Huei-Ting Tsai; Nancy L Keating; Stephen K Van Den Eeden; Arnold L Potosky Journal: Br J Cancer Date: 2017-08-24 Impact factor: 7.640